生物制剂维持治疗下儿童克罗恩病磁共振小肠造影评估的透壁愈合
这项多中心前瞻性观察研究纳入116例未用过抗TNF药物的韩国儿童克罗恩病患者,在基线及生物制剂治疗1年时同步行回结肠镜和磁共振小肠造影。治疗1年时内镜愈合率达59.5%(69/116),透壁愈合率达38.8%(45/116);基线MaRIA评分与透壁愈合相关(OR 0.97,95% CI 0.95-0.99,p=0.023)。作者认为透壁愈合是比内镜愈合更严格的目标。
要点
- 治疗1年时内镜愈合59.5%(69/116),透壁愈合38.8%(45/116),透壁愈合是更严格的目标。
- 达到内镜愈合者中59.4%(41/69)同时有透壁愈合,达到透壁愈合者中91.1%(41/45)同时有内镜愈合。
- 基线MaRIA评分与1年时透壁愈合相关(OR 0.97,95% CI 0.95-0.99,p=0.023)。
核心结论
- 透壁愈合是比内镜愈合更严格的治疗目标。
- 作者认为规律随访透壁状态并努力实现透壁愈合,可能在达标治疗时代改变克罗恩病的自然病程。
研究设计与样本
- 多中心、前瞻性、观察性研究,纳入116例诊断年龄<19岁、未用过抗TNF药物的韩国儿童腔型克罗恩病患者。
- 患者在基线及生物制剂治疗1年时同步接受回结肠镜和磁共振小肠造影检查。
主要发现
- 治疗1年时内镜愈合率为59.5%(69/116),透壁愈合率为38.8%(45/116)。
- 同时达到内镜愈合和透壁愈合者占35.3%(41/116),仅内镜愈合无透壁愈合者占24.1%(28/116),仅透壁愈合无内镜愈合者占3.4%(4/116),两者均未达到者占37.1%(43/116)。
- 达到内镜愈合的患者中59.4%(41/69)有透壁愈合,达到透壁愈合的患者中91.1%(41/45)有内镜愈合。
- 多因素分析显示基线MaRIA评分与透壁愈合相关(OR 0.97,95% CI 0.95-0.99,p=0.023)。
关键数值与推荐
- 治疗1年时内镜愈合59.5%(69/116),透壁愈合38.8%(45/116)。
- 基线MaRIA评分与透壁愈合相关(OR 0.97,95% CI 0.95-0.99,p=0.023)。
临床怎么用
- 作者认为规律随访透壁状态并努力实现透壁愈合,可能在达标治疗时代改变克罗恩病的自然病程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal treatment goal in Crohn's disease (CD) is endoscopic healing (EH). However, transmural healing (TH) facilitated by the development and increasing performance of magnetic resonance enterography (MRE) is emerging as a potential treatment goal. AIMS: To assess TH rates after 1 year of treatment by MRE and its relationship with EH in paediatric patients with CD receiving anti-tumour necrosis factor (TNF) agents, and to investigate factors associated with TH after 1 year of treatment. METHODS: This multi-centre, prospective, observational study included Korean paediatric patients with luminal CD diagnosed at age < 19 years who were naïve to anti-TNF treatment. They simultaneously underwent ileocolonoscopy and MRE at baseline and after 1 year of treatment with biologics. RESULTS: We included 116 patients. At 1 year, EH and TH were achieved in 59.5% (69/116) and 38.8% (45/116) of the patients, respectively. Both EH and TH was observed in 35.3% (41/116), EH without TH in 24.1% (28/116), TH without EH in 3.4% (4/116), and neither EH nor TH in 37.1% (43/116). Moreover, 59.4% (41/69) of patients who achieved EH at 1 year exhibited TH, and 91.1% (41/45) of patients who achieved TH exhibited EH. Baseline MaRIA score was associated with TH according to a multivariate analysis (OR 0.97, 95% CI 0.95-0.99, p = 0.023). CONCLUSION: TH is a more stringent goal than EH. Regular follow-up evaluation of transmural status, and efforts to achieve TH, may alter the natural course of CD in the era of treat-to-target.
引用
- Choi SY, Kim ES, Jeon TY, et al. Transmural healing evaluated by magnetic resonance enterography in paediatric patients with Crohn's disease receiving maintenance treatment with biologics. Aliment Pharmacol Ther. 2022. PMID: 35869849. doi:10.1111/apt.17161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。